Published within
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
...
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
The recent approval for these indications allows Zimmer to compete in the largest segment of the $200 million US market for bone growth substitutes. However, unless the company fully enters the spinal implant market - including the establishment of a spinal salesforce - Collagraft will not reach its sales potential.
Published By Datamonitor
|
01 Nov 2001 |
|
CommentWire
|
Zimmer has released positive preliminary results for its two-incision minimally invasive hip arthroplasty system, and also plans to open a training facility teaching surgeons how to implant these systems. But while the system can radically reduce recovery time, it involves an extremely difficult technique that most orthopaedic surgeons are unlikely to adopt.
Published By Datamonitor
|
24 Jul 2002 |
|
Expert View
|
Statins have become the gold standard in the treatment of dyslipidemia, accounting for approximately 60% of treatments prescribed to patients with coronary heart disease in the late 1990s. However, with these drugs limited in their ability to lower LDL cholesterol to the target recommended by the National Institutes of Health an opportunity awaits for a therapy able to achieve this goal.<BR />
Published By Datamonitor
|
30 May 2003 |
|
CommentWire
|
Following promising Phase II trial results, Zeltia has announced the initiation of an international Phase III clinical trial to investigate a combination of Yondelis and Caelyx. Investigating Yondelis in relapsed ovarian cancer patients theoretically allows for its use in multiple lines of treatment, thereby greatly increasing its future commercial potential.
Published By Datamonitor
|
05 Apr 2005 |
|
CommentWire
|
Zeltia/Johnson & Johnson are seeking US approval for Yondelis, following a pivotal Phase III trial in second-line ovarian cancer therapy. However, approval in this indication may only marginally increase the commercial potential of Yondelis, as competition from established platinum-based chemotherapy agents will restrict the drug's market potential.
Published By Datamonitor
|
24 Nov 2008 |
|
CommentWire
|
Significant, dose responsive increases in mean lumbar spine bone mineral density have been recorded in a four month study of Zelos' parathyroid hormone injections for the treatment of osteoporosis. However, although perhaps indicative of future FDA approval, the positive clinical trials results do not necessarily mean Ostabolin-C will make a significant impact on the osteoporosis market.
Published By Datamonitor
|
09 Feb 2007 |
|
Expert View
|
The FDA has approved Zelboraf and Roche's companion diagnostic test for BRAF V600E mutation-positive metastatic melanoma. The joint approval is the first example of co-development and demonstrates the movement toward personalized cancer therapy, and Zelboraf's impressive efficacy data and the availability of a test will ensure rapid uptake.
Published By Datamonitor
|
18 Aug 2011 |
|
CommentWire
|
Entertainment retailer Zavvi has given an update on its first year of trading following the management buy-out and re-branding in September 2007. The results represent a strong comeback in tough conditions, with like-for-like sales up 10% and annual losses cut by more than GBP10 million, despite an 18% slump in music sales.
Published By Datamonitor
|
17 Sep 2008 |
|
Expert View
|
In recent years, Virgin Megastores, or Zavvi as it is now known, has struggled to break even. While the retailer has worked hard to improve profitability, continued price deflation and rising fixed costs have made this extremely difficult to achieve. Furthermore, with the music market in decline, growing the top line has also proved to be a challenge for Zavvi.
Published By Datamonitor
|
07 Apr 2008 |
|
Expert View
|
For clothing retailers, the UK market presents endless challenges - a low growth market, rising operating costs, and increasing competition. Clothing retailers are therefore looking for new growth opportunities and India, since the relaxation of its foreign entry regulations, has become an attractive target because of its huge growth potential.
Published By Datamonitor
|
04 Sep 2006 |
|
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
...
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.